Infections related to TNF-α inhibitors

Robert Orenstein

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The tumor necrosis factor (TNF)-α inhibitors etanercept, infliximab and adalimumab represent a major therapeutic advance in the treatment of immunologically mediated inflammatory diseases. These agents are already approved for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis and have been used ‘off-label’ in numerous other inflammatory diseases that have been difficult to treat with conventional therapies. Aside from their cost, the principal downside of these agents has been concern regarding infectious complications. Although there are numerous case reports of adverse infectious events, most controlled trials of TNF-inhibitors in rheumatic, cutaneous and gastrointestinal diseases failed to show an increase in the frequency of serious infectious complications beyond that seen with the usual immunosuppressive regimens. Recently, more data have become available from patient cohorts receiving these agents in clinical practice, which have allowed better risk categorization and the development of preventive strategies. This article will review the epidemiology of infectious complications in TNF-inhibitor treated populations, review current guidelines for infection prevention and management and present opportunities for future research in this field.

Original languageEnglish (US)
Pages (from-to)737-749
Number of pages13
JournalExpert Review of Dermatology
Volume1
Issue number5
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Infection
Psoriatic Arthritis
Gastrointestinal Diseases
Ankylosing Spondylitis
Therapeutics
Immunosuppressive Agents
Rheumatic Diseases
Psoriasis
Skin Diseases
Crohn Disease
Rheumatoid Arthritis
Epidemiology
Guidelines
Costs and Cost Analysis
Population

Keywords

  • adalimumab
  • etanercept
  • infections
  • infliximab
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Dermatology

Cite this

Infections related to TNF-α inhibitors. / Orenstein, Robert.

In: Expert Review of Dermatology, Vol. 1, No. 5, 01.10.2006, p. 737-749.

Research output: Contribution to journalArticle

Orenstein, Robert. / Infections related to TNF-α inhibitors. In: Expert Review of Dermatology. 2006 ; Vol. 1, No. 5. pp. 737-749.
@article{0dd07cdcd731482b85f60d71c03be523,
title = "Infections related to TNF-α inhibitors",
abstract = "The tumor necrosis factor (TNF)-α inhibitors etanercept, infliximab and adalimumab represent a major therapeutic advance in the treatment of immunologically mediated inflammatory diseases. These agents are already approved for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis and have been used ‘off-label’ in numerous other inflammatory diseases that have been difficult to treat with conventional therapies. Aside from their cost, the principal downside of these agents has been concern regarding infectious complications. Although there are numerous case reports of adverse infectious events, most controlled trials of TNF-inhibitors in rheumatic, cutaneous and gastrointestinal diseases failed to show an increase in the frequency of serious infectious complications beyond that seen with the usual immunosuppressive regimens. Recently, more data have become available from patient cohorts receiving these agents in clinical practice, which have allowed better risk categorization and the development of preventive strategies. This article will review the epidemiology of infectious complications in TNF-inhibitor treated populations, review current guidelines for infection prevention and management and present opportunities for future research in this field.",
keywords = "adalimumab, etanercept, infections, infliximab, TNF-α inhibitors",
author = "Robert Orenstein",
year = "2006",
month = "10",
day = "1",
doi = "10.1586/17469872.1.5.737",
language = "English (US)",
volume = "1",
pages = "737--749",
journal = "Expert Review of Dermatology",
issn = "1746-9872",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Infections related to TNF-α inhibitors

AU - Orenstein, Robert

PY - 2006/10/1

Y1 - 2006/10/1

N2 - The tumor necrosis factor (TNF)-α inhibitors etanercept, infliximab and adalimumab represent a major therapeutic advance in the treatment of immunologically mediated inflammatory diseases. These agents are already approved for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis and have been used ‘off-label’ in numerous other inflammatory diseases that have been difficult to treat with conventional therapies. Aside from their cost, the principal downside of these agents has been concern regarding infectious complications. Although there are numerous case reports of adverse infectious events, most controlled trials of TNF-inhibitors in rheumatic, cutaneous and gastrointestinal diseases failed to show an increase in the frequency of serious infectious complications beyond that seen with the usual immunosuppressive regimens. Recently, more data have become available from patient cohorts receiving these agents in clinical practice, which have allowed better risk categorization and the development of preventive strategies. This article will review the epidemiology of infectious complications in TNF-inhibitor treated populations, review current guidelines for infection prevention and management and present opportunities for future research in this field.

AB - The tumor necrosis factor (TNF)-α inhibitors etanercept, infliximab and adalimumab represent a major therapeutic advance in the treatment of immunologically mediated inflammatory diseases. These agents are already approved for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis and have been used ‘off-label’ in numerous other inflammatory diseases that have been difficult to treat with conventional therapies. Aside from their cost, the principal downside of these agents has been concern regarding infectious complications. Although there are numerous case reports of adverse infectious events, most controlled trials of TNF-inhibitors in rheumatic, cutaneous and gastrointestinal diseases failed to show an increase in the frequency of serious infectious complications beyond that seen with the usual immunosuppressive regimens. Recently, more data have become available from patient cohorts receiving these agents in clinical practice, which have allowed better risk categorization and the development of preventive strategies. This article will review the epidemiology of infectious complications in TNF-inhibitor treated populations, review current guidelines for infection prevention and management and present opportunities for future research in this field.

KW - adalimumab

KW - etanercept

KW - infections

KW - infliximab

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34250374611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250374611&partnerID=8YFLogxK

U2 - 10.1586/17469872.1.5.737

DO - 10.1586/17469872.1.5.737

M3 - Article

VL - 1

SP - 737

EP - 749

JO - Expert Review of Dermatology

JF - Expert Review of Dermatology

SN - 1746-9872

IS - 5

ER -